Advertisement
Financing › Details
Arrowhead–Silence Therapeutics: investment, 201701 acquisition 6.83m common shares = 9.21% shareholding for $11.3m
Period | 2017-01-09 � 2017-01-13 | |
Successor | Arrowhead–Silence Therapeutics: investment, 201712 DIVESTMENT 2.036m common shares for $7.5m w realised profit of $4.1m | |
Money taker | Arrowhead Pharmaceuticals Inc. (Nasdaq: ARWR) | |
Group | Arrowhead (Group) | |
Money source | Silence Therapeutics plc (Nasdaq: SLN) | |
Group | Silence Therapeutics (Group) | |
Product | RNAi technology | |
Product 2 | RNAi drug (RNAi therapeutic) | |
Silence Therapeutics plc. (1/13/17). "Press Release: Minority Stake in Arrowhead Pharmaceuticals". London.
Silence Therapeutics plc, AIM:SLN (“Silence” or the “Company”) a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, provides an update to its announcement on 9th January 2017 regarding the acquisition of a minority stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) ("Arrowhead").
Silence has today filed a Schedule 13D with the US Securities and Exchange Commission (“Schedule 13D”). Following additional purchases made by the Company since the 9th January, the Schedule 13D sets out that Silence, as at 13th January 2017, directly owns 6,831,359 common shares of Arrowhead, representing 9.21% of the outstanding share capital of Arrowhead. In aggregate, Silence has paid a total consideration of $11.3 million to acquire the 6,831,359 common shares.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU No. 596/2014). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Enquiries:
Silence Therapeutics plc
Ali Mortazavi, Chief Executive Officer
David Ellam, Chief Financial Officer
Tel: +44 (0)20 3457 6900
Canaccord Genuity Limited (Nominated Adviser and Joint Broker)
Rupert Winckler/Henry Fitzgerald-O'Connor/Emma Gabriel
Tel: +44 (0)20 7523 8350
Peel Hunt LLP (Joint Broker)
James Steel/Oliver Jackson
Tel: +44 (0)20 7418 8900
Media Enquiries:
FTI Consulting
Simon Conway/Brett Pollard/Stephanie Cuthbert
Tel: +44 (0) 20 3727 1000
Notes to Editors
About Silence Therapeutics plc
Our technology harnesses the body’s natural mechanisms to create therapeutic effects within its cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo. We have developed proprietary modifications to improve the robustness of RNA sequences, as well as advanced chemistries to enhance the effective delivery of therapeutic RNA molecules to target cells.
Record changed: 2019-12-15 |
Advertisement
More documents for Arrowhead (Group)
- [1] Silence Therapeutics plc. (1/13/17). "Press Release: Minority Stake in Arrowhead Pharmaceuticals". London....
- [2] Silence Therapeutics plc. (1/9/17). "Press Release: Acquisition of Minority Stake in Arrowhead Pharmaceuticals". London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top